Dr Agarwals Eye Hospital Shares Permitted to Trade and Admitted to Dealings on NSE
Dr Agarwals Eye Hospital Limited has been permitted to trade and admitted to dealings for its Equity Shares on the National Stock Exchange of India Limited (NSE). This development allows the company's shares to be traded on the NSE effective from April 20, 2026.The hospital's Equity Shares, which were previously listed and traded exclusively on the BSE Limited under the scrip code 526783, are now available under the symbol 'DRAGARWQ' on the NSE platform.
While the admission to dealings on the NSE has been initiated, the company confirmed that Dr Agarwal's Eye Hospital Limited remains listed only on the BSE Limited and will continue to comply with all listing obligations and disclosure requirements established there.
The primary listing details for the company are as follows:
| Exchange | Status Change | Effective Date | Symbol/Scrip Code |
|---|---|---|---|
| BSE Limited | Previously listed and traded | N/A | 526783 |
| National Stock Exchange (NSE) | Permitted to trade and admitted to dealings | April 20, 2026 | DRAGARWQ |
DRAGARWQ Stock Price Movement
Today, Dr Agarwals Eye Hospital Limited shares edged higher to close at ₹4861.05, rising 2.50% for the session. The equity found support on 821 shares traded today, closing just shy of its 52-week high of ₹4998.00.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.